Oncology

UroGen's new bladder cancer drug sees rapid uptake post-reimbursement code, but a $153M loss and fresh debt highlight its high-stakes growth strategy.

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

Shareholder approval paves the way for cancer therapy innovator VERAXA to go public, aiming to accelerate its next-gen antibody-drug conjugate pipeline.

Facing delisting for being a 'public shell,' XTL Biopharma plans an appeal while its new acquisition and valuable IP hang in the balance.

With U.S. cancer centers tripling adoption of its targeted drug delivery device, RenovoRx signals a potential shift in treating solid tumors.

After securing its Nasdaq spot, TuHURA Biosciences shifts focus to its promising immuno-oncology pipeline, aiming to tackle cancer treatment resistance.

A new study shows alternating magnetic fields can destroy antibiotic-resistant biofilms on medical implants, offering hope for a non-surgical treatment.

Michigan's largest independent oncology practice adds urology, promising patients more coordinated, lower-cost care outside of traditional hospital systems.

A key partnership ensures the supply of a breakthrough therapy for FOP, a devastating condition where muscle turns to bone, highlighting a new era in drug production.

A new skincare brand is skipping mass marketing, embedding its products with veterans, skiers, and melanoma researchers to redefine sun protection.

Spectral Medical shifts its FDA submission for a breakthrough sepsis device, a strategic move that could strengthen its case but delays a potential lifeline.

Kairos Pharma aims to reshape lung cancer treatment by acquiring two AI-designed drugs, targeting a key resistance mechanism in a multi-billion dollar market.

With a key FDA decision looming and pivotal data on a second therapy imminent, Viridian is poised to reshape the multi-billion dollar Thyroid Eye Disease market.

A novel mouse model with human immune receptors promises to slash the high failure rate of antibody therapies, accelerating life-saving treatments.

With its strategic pivot to high-growth Med Tech paying off, all eyes are on AngioDynamics' CEO presentation at the upcoming Leerink healthcare conference.

With stellar clinical data and a full war chest, Terns is hitting the road to convince investors its leukemia drug, TERN-701, is a true disruptor.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

Plus Therapeutics' REYOBIQ gains a crucial CPT code, a vital step in bringing this targeted radiotherapy to patients with aggressive brain cancers.

With $400M in 2025 sales, Immunocore now leverages its KIMMTRAK success to fund a high-stakes pivot into broader cancers, HIV, and autoimmune disease.

A landmark partnership aims to bring precision cancer therapy, or Theranostics, to millions in underserved nations, backed by a major WHO resolution.